Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Similar articles for PubMed (Select 22056257)

1.

Omalizumab for the treatment of atopic dermatitis.

Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S, Suárez Fernández R.

Actas Dermosifiliogr. 2012 Sep;103(7):624-8. Epub 2011 Nov 3. English, Spanish.

PMID:
22056257
2.

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.

Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohé C.

Eur J Med Res. 2011 Sep 12;16(9):407-10.

3.

Omalizumab treatment in severe adult atopic dermatitis.

Thaiwat S, Sangasapaviliya A.

Asian Pac J Allergy Immunol. 2011 Dec;29(4):357-60.

4.

Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.

Kim DH, Park KY, Kim BJ, Kim MN, Mun SK.

Clin Exp Dermatol. 2013 Jul;38(5):496-500. doi: 10.1111/j.1365-2230.2012.04438.x. Epub 2012 Oct 22.

PMID:
23083013
5.

Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.

Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC.

Int Arch Allergy Immunol. 2013;162(1):89-93. doi: 10.1159/000350486. Epub 2013 Jun 27.

6.

Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.

Amrol D.

South Med J. 2010 Jun;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6.

PMID:
20710140
7.

[Dermatological implications of omalizumab, an anti-IgE antibody].

Di Lucca-Chrisment J.

Rev Med Suisse. 2015 Apr 1;11(468):779-80, 782-3. French.

PMID:
26021140
8.

Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.

Sánchez-Ramón S, Eguíluz-Gracia I, Rodríguez-Mazariego ME, Paravisini A, Zubeldia-Ortuño JM, Gil-Herrera J, Fernández-Cruz E, Suárez-Fernández R.

J Investig Allergol Clin Immunol. 2013;23(3):190-6.

9.

Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases.

Toledo F, Silvestre JF, Muñoz C.

J Eur Acad Dermatol Venereol. 2012 Oct;26(10):1325-7. doi: 10.1111/j.1468-3083.2011.04326.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050044
10.

Omalizumab beyond asthma.

Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R.

Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. Epub 2012 Jan 20. Review.

PMID:
22264640
11.

Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.

Ramírez del Pozo ME, Contreras Contreras E, López Tiro J, Gómez Vera J.

J Investig Allergol Clin Immunol. 2011;21(5):416-7. No abstract available.

12.

Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma.

Yalcin AD, Bisgin A, Cetinkaya R, Yildirim M, Gorczynski RM.

Clin Lab. 2013;59(1-2):71-7.

PMID:
23505909
14.

Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.

Scheinfeld N.

Dermatol Online J. 2005 Mar 1;11(1):2. Review.

15.
16.

Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis.

Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG.

Monaldi Arch Chest Dis. 2008 Jun;69(2):78-80.

PMID:
18837422
17.

Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.

D'Amato G, Oldani V, Donner CF.

Monaldi Arch Chest Dis. 2003 Jan-Mar;59(1):25-9. Review.

PMID:
14533279
18.

[Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].

Schmitt J, Schäkel K.

Hautarzt. 2007 Feb;58(2):128, 130-2. German.

PMID:
17237929
19.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators.

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
20.

A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.

D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.

Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. Review.

PMID:
19075985
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk